Literature DB >> 11112093

Effects of imidazole antimycotics on the liver microsomal cytochrome P450 isoforms in rats: comparison of in vitro and ex vivo studies.

S Suzuki1, N Kurata, Y Nishimura, H Yasuhara, T Satoh.   

Abstract

We have studied the effects of three imidazole derivatives, clotrimazole (CLO), ketoconazole (KET) and miconazole (MIC) on the liver microsomal diazepam (DZ) metabolism. In in vitro experiments using rats and human liver microsomes, significant inhibition of CYP3A in terms of DZ-3-hydroxylase activity was observed. The inhibition of DZ metabolism was seen 1 h after CLO dosing. On the other hand, the induction of certain cytochrome P450 (CYP) isozymes was observed in in vivo studies 24 h after dosing. That is, CYP1A, CYP2B and CYP3A2, but not CYP2E, were observed 24 h after CLO or KET or MIC treatment. Under these conditions, CLO was the most potent inducer of CYP3A and MIC was a more potent inducer of CYP1A and CYP2B. KET induced CYP1A and CYP2B whereas the inducibility of KET was less than those of CLO and MIC. All of the imidazole derivatives tested here showed significant inhibition of CYP isozymes which overcame the induction of the CYP isozymes by those drugs in the data of Western blot analysis.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11112093     DOI: 10.1007/BF03190078

Source DB:  PubMed          Journal:  Eur J Drug Metab Pharmacokinet        ISSN: 0378-7966            Impact factor:   2.569


  18 in total

1.  THE CARBON MONOXIDE-BINDING PIGMENT OF LIVER MICROSOMES. I. EVIDENCE FOR ITS HEMOPROTEIN NATURE.

Authors:  T OMURA; R SATO
Journal:  J Biol Chem       Date:  1964-07       Impact factor: 5.157

2.  Comparison of two azole antifungal drugs, ketoconazole, and fluconazole, as modifiers of rat hepatic monooxygenase activity.

Authors:  J B Houston; M J Humphrey; D E Matthew; M H Tarbit
Journal:  Biochem Pharmacol       Date:  1988-02-01       Impact factor: 5.858

Review 3.  The human hepatic cytochromes P450 involved in drug metabolism.

Authors:  S A Wrighton; J C Stevens
Journal:  Crit Rev Toxicol       Date:  1992       Impact factor: 5.635

Review 4.  Molecular genetics of the P-450 superfamily.

Authors:  F J Gonzalez
Journal:  Pharmacol Ther       Date:  1990       Impact factor: 12.310

Review 5.  Human cytochrome P-450 enzymes.

Authors:  F P Guengerich
Journal:  Life Sci       Date:  1992       Impact factor: 5.037

6.  Applications of primary human hepatocytes in the evaluation of pharmacokinetic drug-drug interactions: evaluation of model drugs terfenadine and rifampin.

Authors:  A P Li; M Jurima-Romet
Journal:  Cell Biol Toxicol       Date:  1997-07       Impact factor: 6.691

Review 7.  Inhibition of terfenadine metabolism. Pharmacokinetic and pharmacodynamic consequences.

Authors:  K T Kivistö; P J Neuvonen; U Klotz
Journal:  Clin Pharmacokinet       Date:  1994-07       Impact factor: 6.447

Review 8.  Cyclosporin and ketoconazole, drug interaction or therapeutic association?

Authors:  E Albengres; J P Tillement
Journal:  Int J Clin Pharmacol Ther Toxicol       Date:  1992-12

9.  Characterization of specific cytochrome P450 enzymes responsible for the metabolism of diazepam in hepatic microsomes of adult male rats.

Authors:  C F Neville; S Ninomiya; N Shimada; T Kamataki; S Imaoka; Y Funae
Journal:  Biochem Pharmacol       Date:  1993-01-07       Impact factor: 5.858

10.  Torsades de pointes occurring in association with terfenadine use.

Authors:  B P Monahan; C L Ferguson; E S Killeavy; B K Lloyd; J Troy; L R Cantilena
Journal:  JAMA       Date:  1990-12-05       Impact factor: 56.272

View more
  6 in total

1.  Therapeutic potential of KCa3.1 blockers: recent advances and promising trends.

Authors:  Heike Wulff; Neil A Castle
Journal:  Expert Rev Clin Pharmacol       Date:  2010-05       Impact factor: 5.045

2.  Intestinal epithelial potassium channels and CFTR chloride channels activated in ErbB tyrosine kinase inhibitor diarrhea.

Authors:  Tianying Duan; Onur Cil; Jay R Thiagarajah; Alan S Verkman
Journal:  JCI Insight       Date:  2019-02-21

Review 3.  Senicapoc: Repurposing a Drug to Target Microglia KCa3.1 in Stroke.

Authors:  Roland G W Staal; Jonathan R Weinstein; Megan Nattini; Manuel Cajina; Gamini Chandresana; Thomas Möller
Journal:  Neurochem Res       Date:  2017-03-31       Impact factor: 3.996

4.  Functional Analysis of the Unique Cytochrome P450 of the Liver Fluke Opisthorchis felineus.

Authors:  Mariya Y Pakharukova; Valentin A Vavilin; Banchob Sripa; Thewarach Laha; Paul J Brindley; Viatcheslav A Mordvinov
Journal:  PLoS Negl Trop Dis       Date:  2015-12-01

5.  TRAM-34, a putatively selective blocker of intermediate-conductance, calcium-activated potassium channels, inhibits cytochrome P450 activity.

Authors:  Jay J Agarwal; Yi Zhu; Qing-Yu Zhang; Alexander A Mongin; Lindsay B Hough
Journal:  PLoS One       Date:  2013-05-07       Impact factor: 3.240

6.  KCa3.1 Channel Modulators as Potential Therapeutic Compounds for Glioblastoma.

Authors:  Brandon M Brown; Brandon Pressley; Heike Wulff
Journal:  Curr Neuropharmacol       Date:  2018       Impact factor: 7.363

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.